{
    "paper_id": "PMC7243755",
    "metadata": {
        "title": "Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR detection of SARS-CoV-2 from nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard: an example of the need of validation studies",
        "authors": [
            {
                "first": "Byron",
                "middle": [],
                "last": "Freire-Paspuel",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Patricio",
                "middle": [],
                "last": "Vega-Mari\u00f1o",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Alberto",
                "middle": [],
                "last": "Velez",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Paulina",
                "middle": [],
                "last": "Castillo",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Marilyn",
                "middle": [],
                "last": "Cruz",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Miguel",
                "middle": [
                    "Angel"
                ],
                "last": "Garcia-Bereguiain",
                "suffix": "",
                "email": "magbereguiain@gmail.com",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Multiple in vitro RT-qPCR diagnosis kits are available on the market for the detection of SARS-CoV-2. Some of them have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) while others only report validations made by manufacturers, and in general little is known about their performances using clinical specimens. The CDC designed 2019-nCoV CDC EUA kit (IDT, USA) is based on N1 and N2 probes to detect SARS-CoV-2 that have received positive evaluation on recent reports [[1], [2], [3]], and and RNase P as an RNA extraction quality control. Other kit avalaible in the market is nCoV-QS (MiCo BioMed; South Corea) that include probes \"ORF3a\" and \"N\" probes for SARS-CoV-2 detection but no probe for RNA extraction quality control, with no EUA approval neither from FDA (USA) nor from Korean CDC [[4], [5], [6]].",
            "cite_spans": [
                {
                    "start": 510,
                    "end": 513,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 515,
                    "end": 518,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 520,
                    "end": 523,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 834,
                    "end": 837,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 839,
                    "end": 842,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 844,
                    "end": 847,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "Background",
            "ref_spans": []
        },
        {
            "text": "This study compared the performance in terms of positive percent agreement (PPA) of nCoV-QS (MiCo BioMed; South Corea) and 2019-nCoV CDC EUA kit (IDT, USA) primers and probes for SARS-CoV-2 qPCR diagnosis from nasopharyngeal samples.",
            "cite_spans": [],
            "section": "Objective",
            "ref_spans": []
        },
        {
            "text": "Fifty-four (54) clinical specimens (nasopharyngeal swabs collected on 0.5 mL TE pH 8 buffer) from patients selected as suspicious for SARS-CoV-2 infection were included on this study during the surveillance in Galapagos Islands started on April 8th 2020. Also, six negative controls (TE pH 8 buffer) were included as control for carryover contamination. Both CoV-QS and 2019-nCoV CDC EUA kits were used at SARS-CoV-2 diagnosis laboratory \"LabGal\" at \"Agencia de Regulaci\u00f3n y Control de la Bioseguridad y Cuarentena para Gal\u00e1pagos\" at Puerto Ayora in Galapagos Islands (Ecuador), where we considered this validation necessary to guarantee the sensibility of SARS-CoV-2 during the surveillance.",
            "cite_spans": [],
            "section": "Study design",
            "ref_spans": []
        },
        {
            "text": "Twenty-five (25) samples were tested following an adapted version of the CDC protocol [1] using CFX96 BioRad instrument and PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) as an alternate RNA extraction method, and also interpreting as positive 3 samples where a probe was positive with Ct<40 and the second one with Ct values up to 41.15 (See Table 1\nand Table 2\na). We performed this protocol for both nCoV-QS and 2019-nCoV CDC EUA primers and probes kits. Nine samples were negative for both kits; Sixteen samples were positive for 2019-nCoV CDC EUA (range of Ct values: 23.02-41.15 for N1; 24.08-40.12 for N2), but only ten (PPA 62.5%; p < 0.001) of those ones were positive for nCoV-QS (range of Ct values: 28.71-39.98 for ORF3a; 24.48-35.44 for N). Results are detailed on Table 1a. The assay was validated to detect 20 viral RNA copies/uL by using 2019-nCoV N positive control (IDT, USA).",
            "cite_spans": [
                {
                    "start": 87,
                    "end": 88,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 346,
                    "end": 353,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 358,
                    "end": 365,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 781,
                    "end": 788,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Twenty-nine (29) samples were tested following instructions manual from MiCo BioMed for nCoV-QS kit [6], using MiCo BioMed One RT-qPCR kit. PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) was used for RNA extraction. We performed this protocol for both nCoV-QS and 2019-nCoV CDC EUA primers and probes kits. Twelve samples were negative for both kits; Seventeen samples were positive for 2019-nCoV CDC EUA (range of Ct values: 23.1-39.05 for N1; 22.96-38.8 for N2), but only 12 (PPA 70.5%; p < 0.001) of those ones were positive for nCoV-QS (range of Ct values: 26.45-39.43 for ORF3a; 24.03-39.89 for N). Results are detailed on Table 1, Table 2b. We used CFX96 BioRad to run qPCR but also results were confirmed using Veri-Q PCR316 instrument from MiCo BioMed [4]. The assay sensitivity indicated on manufacturers manual (1.8 copies/uL for OFR3a and 4.24 copies/uL for N) could not be validated because positive control concentration was not provided.",
            "cite_spans": [
                {
                    "start": 101,
                    "end": 102,
                    "mention": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 764,
                    "end": 765,
                    "mention": "4",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 631,
                    "end": 638,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 640,
                    "end": 647,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "In summary, overall PPA for nCoV-QS was 66.7% (22 out of 33 positives samples for 2019-nCoV CDC EUA; p < 0.001), and 70.5% and 62.5% for MiCo BioMed and adapted CDC protocols, respectively. Additionally, considering the viral loads calculated following adapted CDC protocol with 2019-nCoV N positive control (IDT, USA), the limit of detection (viral copies/uL) for nCoV-QS kit is much higher than the one indicated at manufacturer's manual [6].",
            "cite_spans": [
                {
                    "start": 441,
                    "end": 442,
                    "mention": "6",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "Results",
            "ref_spans": []
        },
        {
            "text": "Although the main limitation of our study is the sample size (54 specimens), our results support that nCoV-QS kit had a significant lower performance in terms on PPA and sensitivity compared to 2019-nCoV CDC EUA. Also, the lack of any probe for RNA extraction quality control like RNase P and the unreported concentration of positive controls provided for the kit that does not allow viral load calculations, are limitations to be considered when using nCoV-QS kit.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Considering the worldwide high demand of reagents for SARS-CoV RT-qPCR diagnosis, supplies shortage is a fact, actually affecting harder to developing countries like Ecuador. Under this scenario, validation studies are helpful to guarantee the quality of the supplies in the market for every country in the world.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "All samples have been submitted for routine patient care and diagnostics. Ethical approval for this study was not required since all activities are according to legal provisions defined by the \"Comit\u00e9 de Operaciones Especiales Regional de Gal\u00e1pagos\" that is leading the Covid19 surveillance in Galapagos Islands. No extra specimens were specifically collected for this validation study. All data used in the current study was anonymized prior to being obtained by the authors.",
            "cite_spans": [],
            "section": "Ethical considerations",
            "ref_spans": []
        },
        {
            "text": "All authors contributed to study conceptualization, experimental procedures and revision and approval of final version of the manuscript.",
            "cite_spans": [],
            "section": "Authorship contribution statement",
            "ref_spans": []
        },
        {
            "text": "Byron Freire-Paspuel and Miguel Angel Garc\u00eda Bereguiain analyzed the data and wrote the manuscript.",
            "cite_spans": [],
            "section": "Authorship contribution statement",
            "ref_spans": []
        },
        {
            "text": "None.",
            "cite_spans": [],
            "section": "Funding",
            "ref_spans": []
        },
        {
            "text": "All authors have no conflict of interest to declare.",
            "cite_spans": [],
            "section": "Declaration of Competing Interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Performance of nCoV-QS compared to 2019-nCoV CDC EUA for RT-qPCR SARS-CoV-2 diagnosis (% values: PPA).\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Ct values for nCoV-QS and 2019-nCoV CDC EUA RT-qPCR using CDC adapted protocol for 25 samples (a) and MiCoBioMed protocol for 29 samples (b).\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [],
            "year": 2019,
            "venue": "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19",
            "authors": [
                {
                    "first": "Daniel",
                    "middle": [
                        "D."
                    ],
                    "last": "Rhoads",
                    "suffix": ""
                },
                {
                    "first": "Sree",
                    "middle": [
                        "S."
                    ],
                    "last": "Cherian",
                    "suffix": ""
                },
                {
                    "first": "Katharine",
                    "middle": [],
                    "last": "Roman",
                    "suffix": ""
                },
                {
                    "first": "Lisa",
                    "middle": [
                        "M."
                    ],
                    "last": "Stempak",
                    "suffix": ""
                },
                {
                    "first": "Christine",
                    "middle": [
                        "L."
                    ],
                    "last": "Schmotzer",
                    "suffix": ""
                },
                {
                    "first": "Navid",
                    "middle": [],
                    "last": "Sadri",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J. Clin. Microbiol.",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1128/JCM.00760-20"
                ]
            }
        },
        "BIBREF2": {
            "title": "Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit. Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit",
            "authors": [
                {
                    "first": "Arun",
                    "middle": [
                        "K."
                    ],
                    "last": "Nallaa",
                    "suffix": ""
                },
                {
                    "first": "Amanda",
                    "middle": [
                        "M."
                    ],
                    "last": "Castob",
                    "suffix": ""
                },
                {
                    "first": "Meei-Li",
                    "middle": [
                        "W."
                    ],
                    "last": "Huanga",
                    "suffix": ""
                },
                {
                    "first": "Garrett",
                    "middle": [
                        "A."
                    ],
                    "last": "Perchettia",
                    "suffix": ""
                },
                {
                    "first": "Reigran",
                    "middle": [],
                    "last": "Sampoleoa",
                    "suffix": ""
                },
                {
                    "first": "Lasata",
                    "middle": [],
                    "last": "Shresthaa",
                    "suffix": ""
                },
                {
                    "first": "Yulun",
                    "middle": [],
                    "last": "Weia",
                    "suffix": ""
                },
                {
                    "first": "Haiying",
                    "middle": [],
                    "last": "Zhua",
                    "suffix": ""
                },
                {
                    "first": "Keith",
                    "middle": [
                        "R."
                    ],
                    "last": "Jeromea",
                    "suffix": ""
                },
                {
                    "first": "Alexander",
                    "middle": [
                        "L."
                    ],
                    "last": "Greningera",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J. Clin. Microbiol.",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1128/JCM.00557-20"
                ]
            }
        },
        "BIBREF3": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "On behalf of Korean Society for Laboratory Medicine, COVID-19 Task Force and the Center for Laboratory Control of Infectious Diseases, the Korea Centers for Disease Control and Prevention. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea",
            "authors": [
                {
                    "first": "Ho",
                    "middle": [
                        "Hong"
                    ],
                    "last": "Ki",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Ann Lab Med",
            "volume": "",
            "issn": "40",
            "pages": "351-360",
            "other_ids": {
                "DOI": [
                    "10.3343/alm.2020.40.5.351"
                ]
            }
        },
        "BIBREF5": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}